MGC Pharma Ltd co-founder and managing director Roby Zomer joined Proactive’s Stephen Gunnion with news that the company was granted approval by the Indian authorities to import its phytomedicine CimetrA into that country as a final step towards obtaining emergency-use authorisation for the treatment of patients with coronavirus (COVID-19).
Zomer telling Proactive that India has been acutely affected by the COVID-19 pandemic and MGC Pharma believes that CimetrA can make an important difference in treating the symptoms of COVID-19 and alleviating patient suffering.